Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
What they do
Iktos specializes in generative artificial intelligence applied to chemical research. The company offers software for synthetic planning and automated molecule design, enabling medicinal chemists to discover novel clinical candidates more efficiently.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Paris, France
- Region
- Europe
- Founded
- 2016
- Total funding
- $16M raised
Notable investors: Omnes Capital, M Ventures, Debiopharm Innovation Fund.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA